(Q34743314)

4 August 2017

title

Physicians' preferences for active-controlled versus placebo-controlled trials of new antihypertensive drugs (English)

1 reference

4 August 2017

0 references

David A Asch

5

0 references

Peter A. Ubel

series ordinal

2

object named as

Peter A Ubel

1 reference

4 August 2017

Scott D Halpern

1

1 reference

4 August 2017

Jesse A Berlin

series ordinal

3

1 reference

4 August 2017

Raymond R Townsend

series ordinal

4

1 reference

4 August 2017

publication date

1 September 2002

1 reference

Journal of General Internal Medicine

4 August 2017

published in

1 reference

4 August 2017

volume

17

1 reference

4 August 2017

issue

9

1 reference

4 August 2017

page(s)

689-695

1 reference

https://scigraph.springernature.com/pub.10.1046/j.1525-1497.2002.11024.x

4 August 2017

exact match

0 references

cites work

Scientific value and validity as ethical requirements for research: a proposed explication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Who will enroll? Predicting participation in a phase II AIDS vaccine trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

What makes clinical research ethical?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Is the use of placebo in antihypertensive drug studies ethical?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Validity versus generalizability in clinical trial design and conduct.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Trials to assess equivalence: the importance of rigorous methods

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Scientific challenges in the application of randomized trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Impact of randomized clinical trials on medical practices

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Tribulations for clinical trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Randomised clinical trials with clinician-preferred treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Integrating conflicting professional roles: physician participation in randomized clinical trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Ethical considerations in the planning of hypertension treatment trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

The ethics of using placebo in hypertension clinical trials.

7 July 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.2002.11024.X

Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.2002.11024.X

Placebo-controlled trials are unethical in clinical hypertension research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.2002.11024.X

When are clinical trials of a given agent vs. placebo no longer appropriate or feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.2002.11024.X

Randomized trial of 5 dollars versus 10 dollars monetary incentives, envelope size, and candy to increase physician response rates to mailed questionnaires

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.2002.11024.X

Breast cancer prevention study aims to overcome drug bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.2002.11024.X

Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.2002.11024.X

Placebo-controlled trials in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.2002.11024.X

The Placebo Problem Remains

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-1497.2002.11024.X

Statistical analysis to settle ethical issues?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1495099

Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer

9 December 2018

1 reference

12 December 2020

Physician participation in a randomized clinical trial for ocular melanoma

1 reference

12 December 2020

An additional basic science for clinical medicine: II. The limitations of randomized trials

1 reference

12 December 2020

Inadequate Management of Blood Pressure in a Hypertensive Population

1 reference

12 December 2020

Design and interpretation of equivalence trials

1 reference

12 December 2020

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

1 reference

12 December 2020

10.1046/J.1525-1497.2002.11024.X

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference

4 August 2017

1 reference